https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-842014-08-05 00:00:002019-02-15 08:46:15Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 3; abstr 69)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 3; abstr 69)2014-07-31 12:08:122019-09-30 09:32:18The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-31 / J Clin Oncol 32, 2014 (suppl 4; abstr 490)2014-07-31 11:52:432021-08-09 07:54:15A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-22 / J Transl Med 2014 Jul;12:209
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-22 / J Transl Med 2014 Jul;12:2092014-07-22 00:00:002019-02-15 08:48:43Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised „proof-of-principle“ phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-17 / Am. J. Ophthalmol. 2014 Nov;158(5):939-47
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-17 / Am. J. Ophthalmol. 2014 Nov;158(5):939-472014-07-17 00:00:002019-02-15 08:49:40Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-01 / Immunology 2014 Jul;142(3):396-405
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-01 / Immunology 2014 Jul;142(3):396-4052014-07-01 00:00:002019-02-15 08:49:49Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-01 / Yonsei Med. J. 2014 Jul;55(4):1014-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-01 / Yonsei Med. J. 2014 Jul;55(4):1014-272014-07-01 00:00:002019-02-15 08:52:43Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-952014-06-30 00:00:002019-02-15 08:52:07Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-402014-06-09 00:00:002019-02-15 08:52:08Ovarian cancer biology and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)2014-06-01 12:06:002019-07-17 12:06:29Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
